[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

about

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.

P2860

Q38754136-EBCDCC59-17D2-4C72-8731-2C004073D121

P2860

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

Item

http://www.wikidata.org/entity/Q54195816

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@en

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@nl

type

Item

label

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@en

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@nl

prefLabel

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@en

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@nl

P1476

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

@en

P2093

B Keck

http://www.w3.org/2001/XMLSchema#string

D Sikic

http://www.w3.org/2001/XMLSchema#string

N Meidenbauer

http://www.w3.org/2001/XMLSchema#string

V Lieb

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

P304

952-955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00120-016-0089-2

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27146871

http://www.w3.org/2001/XMLSchema#string

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

about

P2860

P2860

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698